Plant Name: Datura inoxia
Taxonomic Information:
Plant ID: NPO21393
Plant Latin Name: Datura inoxia
Taxonomy Genus: Datura
Taxonomy Family: Solanaceae
Plant External Links:
NCBI TaxonomyDB:
4075
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
IndiaTraditional Medicine System:
AyurvedaMedicinal Functions:
Anodyne; Antispasmodic; Hallucinogenic; Hypnotic; Narcotic
Geographical Distribution:
India
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CHRM1; CHRM2; CHRM3; CHRM5; | |
| TSHR; | |
| BLM; HSD17B10; USP2; POLB; | |
| MAPK1; | |
| HIF1A; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
| Small molecule receptor (family A GPCR) | CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 | CHEMBL211 |
| Small molecule receptor (family A GPCR) | CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 | CHEMBL245 |
| Small molecule receptor (family A GPCR) | CHRM5 | Muscarinic acetylcholine receptor M5 | P08912 | CHEMBL2035 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0007197; adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway | 4.267E-13 | 4.646E-09 | CHRM1, CHRM2, CHRM3, CHRM5 |
| MF | GO:0060089; molecular transducer activity | GO:0016907; G-protein coupled acetylcholine receptor activity | 4.267E-13 | 4.646E-09 | CHRM1, CHRM2, CHRM3, CHRM5 |
| BP | GO:0050896; response to stimulus | GO:0007207; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway | 1.280E-12 | 9.288E-09 | CHRM1, CHRM2, CHRM3, CHRM5 |
| BP | GO:0023052; signaling | GO:0007271; synaptic transmission, cholinergic | 1.487E-09 | 4.047E-06 | CHRM1, CHRM2, CHRM3, CHRM5 |
| MF | GO:0003824; catalytic activity | GO:0004435; phosphatidylinositol phospholipase C activity | 5.313E-07 | 6.701E-04 | CHRM1, CHRM3, CHRM5 |
| BP | GO:0032501; multicellular organismal process | GO:0046541; saliva secretion | 3.534E-06 | 3.207E-03 | CHRM1, CHRM3 |
| CC | GO:0044456; synapse part | GO:0043679; axon terminus | 4.719E-06 | 4.110E-03 | CHRM1, CHRM2, CHRM3 |
| CC | GO:0044456; synapse part | GO:0045211; postsynaptic membrane | 6.396E-06 | 5.158E-03 | CHRM1, CHRM2, CHRM3, CHRM5 |
| CC | GO:0045202; synapse | GO:0032279; asymmetric synapse | 9.886E-06 | 6.523E-03 | CHRM2, CHRM3 |
| BP | Unclassified; | GO:0003056; regulation of vascular smooth muscle contraction | 1.271E-05 | 7.905E-03 | CHRM1, CHRM3 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 3.692E-09 | 3.877E-07 | CHRM2, CHRM3, CHRM1, CHRM5, MAPK1 |
| 09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 9.973E-08 | 5.236E-06 | CHRM2, CHRM3, CHRM1, CHRM5, MAPK1 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 3.596E-07 | 1.259E-05 | CHRM2, CHRM3, CHRM1, CHRM5, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 2.969E-06 | 7.794E-05 | CHRM2, CHRM3, CHRM1, CHRM5 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 4.423E-06 | 9.287E-05 | CHRM2, CHRM1, MAPK1, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 5.729E-04 | 9.372E-03 | MAPK1, HIF1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 9.641E-04 | 1.125E-02 | CHRM2, CHRM1, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 6.929E-04 | 9.372E-03 | MAPK1, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 7.140E-04 | 9.372E-03 | MAPK1, HIF1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.676E-03 | 1.600E-02 | MAPK1, HIF1A |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Visceral spasms | R25.2 | CHRM1; |
| NA: NA | Schizoaffective disorders | NA | CHRM1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRM1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Postoperative nausea and vomiting | R11 | CHRM3; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Stabilize muscle contractions | M00-M99 | CHRM2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Sjogren's syndrome | M35.0 | CHRM3; |
| NA: NA | Addiction | NA | CHRM2; |
| K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | CHRM1; CHRM5; |
| NA: NA | Functional bowel syndrome | NA | CHRM1; |
| NA: NA | Spasms | NA | CHRM3; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | CHRM1; CHRM5; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CHRM1; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | CHRM1; CHRM5; |
| NA: NA | Excessive sweating | NA | CHRM1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | CHRM5; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | CHRM1; CHRM2; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | CHRM1; CHRM2; |
| NA: NA | Dystonia | NA | CHRM1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | CHRM5; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | CHRM5; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | CHRM1; CHRM3; |
| N00-N99: Diseases of the genitourinary system | Overactive bladder | N32.81 | CHRM3; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | CHRM2; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | CHRM1; CHRM2; CHRM3; CHRM5; |
| K00-K95: Diseases of the digestive system | Colitis | K50-K52 | CHRM5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | CHRM1; CHRM5; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CHRM3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | CHRM2; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnosing bronchial hyperreactivity | W88 | CHRM3; |
| G00-G99: Diseases of the nervous system G00-G99 | Central and peripheral nervous diseases | G96.9 | CHRM5; |
| J00-J99: Diseases of the respiratory system | Obstructive lung diseases | J40-J44, J47 | CHRM3; |
| NA: NA | Extrapyramidal disorders secondary to neuroleptic drug therapy | NA | CHRM1; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | CHRM3; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CHRM2; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CHRM1; CHRM3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | CHRM1; |
| G00-G99: Diseases of the nervous system G00-G99 | Brain diseases | G00-G99 | CHRM5; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | CHRM2; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | CHRM1; CHRM2; CHRM3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Amnesia | F04 | CHRM5; |
| NA: NA | Abdominal stomach pain | NA | CHRM1; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | CHRM1; CHRM3; CHRM5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CHRM1; CHRM5; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Seborrhea | L21 | CHRM3; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
